公开(公告)号：EP2167485A2

公开(公告)日：2010-03-31

申请号：EP08768008.8

申请日：2008-05-30

申请人： Genzyme Corporation

发明人： SIEGEL, Craig ,  BASTOS, Cecilia, M. ,  HARRIS, David, J. ,  DIOS, Angeles ,  LEE, Edward ,  SILVA, Richard ,  CUFF, Lisa, M. ,  LEVINE, Mikaela ,  CELATKA, Cassandra ,  VINICK, Frederic ,  JOZEFIAK, Thomas ,  XIANG, Yibin ,  KANE, John ,  LIAO, Junkai

IPC分类号： C07D319/18 ,  C07D405/06 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D411/12 ,  C07D413/12 ,  C07D413/14 ,  C07D295/125 ,  A61K31/357 ,  A61P3/10

CPC分类号： C07D417/14 ,  C07D295/125 ,  C07D319/18 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D411/12 ,  C07D413/12 ,  C07D413/14

摘要： A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-±, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

摘要翻译： 化合物由结构式（I）表示：或其药学上可接受的盐。 药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。 治疗有此需要的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。 受试者患有2型糖尿病; 与糖尿病肾病相关的肾肥大或增生; 戴萨克斯; 高雪; 或法布里病。 在有此需要的受试者中降低血浆TNF-α，降低血糖水平，降低糖化血红蛋白水平，抑制葡萄糖神经酰胺合酶和降低鞘糖脂浓度的方法包括向受试者施用治疗有效量的由结构式 I）或其药学上可接受的盐。

公开(公告)号：EP2349255B1

公开(公告)日：2016-03-30

申请号：EP09741487.4

申请日：2009-10-02

申请人： Genzyme Corporation

发明人： SIEGEL, Craig ,  BASTOS, Cecilia, M. ,  HARRIS, David, J. ,  DIOS, Angeles ,  LEE, Edward ,  SILVA, Richard ,  CUFF, Lisa, M. ,  LEVINE, Mikaela ,  CELATKA, Cassandra, A. ,  JOZEFIAK, Thomas, H. ,  VINICK, Frederic ,  XIANG, Yibin ,  KANE, John ,  LIAO, Junkai

IPC分类号： A61K31/4025 ,  C07C271/12 ,  C07D207/10 ,  C07D295/04 ,  C07D295/10 ,  C07D319/08 ,  C07D405/06 ,  C07D405/14 ,  C07D407/14 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/14

CPC分类号： A61K31/4025 ,  C07C271/12 ,  C07D207/12 ,  C07D317/60 ,  C07D319/18 ,  C07D319/20 ,  C07D333/16 ,  C07D407/06 ,  C07D407/12 ,  C07D409/04 ,  C07D413/04 ,  C07D417/12

公开(公告)号：EP2167485B1

公开(公告)日：2015-09-30

申请号：EP08768008.8

申请日：2008-05-30

申请人： Genzyme Corporation

发明人： SIEGEL, Craig ,  BASTOS, Cecilia, M. ,  HARRIS, David, J. ,  DIOS, Angeles ,  LEE, Edward ,  SILVA, Richard ,  CUFF, Lisa, M. ,  LEVINE, Mikaela ,  CELATKA, Cassandra ,  VINICK, Frederic ,  JOZEFIAK, Thomas ,  XIANG, Yibin ,  KANE, John ,  LIAO, Junkai

IPC分类号： C07D319/18 ,  C07D405/06 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D411/12 ,  C07D413/12 ,  C07D413/14 ,  C07D295/125 ,  A61K31/357 ,  A61P3/10

CPC分类号： C07D417/14 ,  C07D295/125 ,  C07D319/18 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D411/12 ,  C07D413/12 ,  C07D413/14

摘要： A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-±, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP2349255A1

公开(公告)日：2011-08-03

申请号：EP09741487.4

申请日：2009-10-02

申请人： Genzyme Corporation

发明人： SIEGEL, Craig ,  BASTOS, Cecilia, M. ,  HARRIS, David, J. ,  DIOS, Angeles ,  LEE, Edward ,  SILVA, Richard ,  CUFF, Lisa, M. ,  LEVINE, Mikaela ,  CELATKA, Cassandra, A. ,  JOZAFIAK, Thomas, H. ,  VINICK, Frederic ,  XIANG, Yibin ,  KANE, John ,  LIAO, Junkai

IPC分类号： A61K31/4025 ,  C07C271/12 ,  C07D207/10 ,  C07D295/04 ,  C07D295/10 ,  C07D319/08 ,  C07D405/06 ,  C07D405/14 ,  C07D407/14 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/14

CPC分类号： A61K31/4025 ,  C07C271/12 ,  C07D207/12 ,  C07D317/60 ,  C07D319/18 ,  C07D319/20 ,  C07D333/16 ,  C07D407/06 ,  C07D407/12 ,  C07D409/04 ,  C07D413/04 ,  C07D417/12

摘要： A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

摘要翻译： 用于治疗多囊肾病的化合物由结构式（I）表示：或其药学上可接受的盐。 药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。 治疗有需要的受试者的多囊肾病的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。 在有需要的受试者中治疗多囊肾病的方法分别包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。